


PHARMACEUTICAL 2017

REVANCE°

Revance Therapeutics Inc. Rank 140 of 313





PHARMACEUTICAL 2017

REVANCE°

Revance Therapeutics Inc. Rank 140 of 313

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 297% points. The greatest weakness of Revance Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -145%, being 272% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	192,695
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,647
Liabilities, Non-Current	100
Other Assets	1,080
Other Compr. Net Income	-5.0
Other Expenses	10,141
Other Liabilities	7,542
Other Net Income	27
Property and Equipment	10,585
Research and Development	50,381
Revenues	300
Selling, General and Administrative Expense	29,075

Output Variable	Value in 1000 USD
Assets	204,360
Liabilities	27,289
Expenses	89,597
Stockholders Equity	177,071
Net Income	-89,270
Comprehensive Net Income	-89,272
Economic Capital Ratio	-145%